New oncology innovators join the PSCC BOOST programme
- 6 hours ago
- 2 min read
This quarter, eight innovative oncology-focused projects have been selected to join the BOOST programme of the Paris Saclay Cancer Cluster (PSCC), further strengthening the diversity, scientific excellence, and international reach of the ecosystem.
From cancer vaccines and oncolytic viruses to precision immunotherapies, ADC technologies, photodynamic therapies, and innovative diagnostics, these projects illustrate the breadth of approaches supported by PSCC to accelerate the translation of scientific breakthroughs into tangible impact for patients.
The newly selected projects
CEREUS Biosciences- This biotech explores the dark genome to uncover a new class of shared tumour-specific neoantigens, enabling the development of next-generation off-the-shelf cancer vaccines.
HEMERION Therapeutics- A healthtech company developing a novel intraoperative photodynamic therapy combining a photosensitising drug and a laser device to selectively destroy residual brain tumour cells.
IMMUNOEDGE- A German techbio company developing advanced peptidomics and proteomics technologies to identify clinically relevant tumour antigens from minimal biopsies, enabling target discovery and monitoring for next-generation immunotherapies.
MABQI- Developing a first-in-class antibody targeting a calcium onco-channel, a pan-cancer target found across multiple solid tumours, with an initial focus on metastatic castration-resistant prostate cancer (mCRPC).
OMIOS Biological- A US-based biotech developing the first biomarker-guided, non-attenuated oncolytic virus platform engineered for systemic intravenous delivery and selective replication in cancer cells.
PAPILIO.BIO- A medtech company developing a rapid at-home molecular self-test and companion app for HPV detection, enabling early and accessible screening to help prevent HPV-related cancers.
SPIREA- A UK-based biotech developing its proprietary ELIVATE linker technology, significantly expanding the range of therapeutic payloads that can be used in antibody-drug conjugates (ADCs).
Unguard Therapeutics- Developing first-in-class small molecules for cancers with homologous recombination deficiency (HRD), with an initial focus on ovarian cancers resistant to PARP inhibitors.
Comprehensive support for oncology innovation
With 84 projects selected to date, PSCC provides comprehensive support, from scientific expertise and access to funding, to partnerships, data, technologies, infrastructures, and laboratories, helping transform pioneering ideas into real impact for patients.
By bringing together entrepreneurs, researchers, clinicians, investors, patient representatives, and industry leaders, PSCC aims to accelerate the development of the next generation of oncology innovations and strengthen Europe’s leadership in cancer research and innovation.
Apply to the BOOST programme
Are you developing an innovative oncology solution? Discover how to apply to the BOOST programme:
